Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-13T04:23:12.461Z Has data issue: false hasContentIssue false

PW01-181 - Economic Consequences Of Medication Nonadherence In The Treatment Of Schizophrenia: 36-Month Results From The Soho (Schizophrenia Outpatient Health Outcomes) Study

Published online by Cambridge University Press:  17 April 2020

J. Hong
Affiliation:
Personal Social Services Research Unit (PSSRU), London School of Economics, London, UK European Health Outcomes Research, Eli Lilly and Company, Windlesham, UK
D. Novick
Affiliation:
European Health Outcomes Research, Eli Lilly and Company, Windlesham, UK
J.M. Haro
Affiliation:
Sant Joan de Deu-SSM, Sant Boi, Barcelona, Spain
M. Knapp
Affiliation:
Personal Social Services Research Unit (PSSRU), London School of Economics, London, UK Centre for the Economics of Mental Health, Institute of Psychiatry, London, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To estimate costs associated with medication non-adherence over a 3-year follow-up period in the treatment of schizophrenia in routine clinical practice in Europe.

Methods

SOHO is a 3-year, prospective, observational study of 10972 outpatient participants across 10 European countries. Data were collected at baseline and at 6-month intervals up to 36 months. Medication adherence was assessed at each visit by participating psychiatrists during 4 weeks prior to the visit as: (1) not prescribed medication; (2) always adherent; (3) partially adherent; and (4) never adherent. In this post-hoc analysis, multivariate analyses were performed to compare the costs of resource use (inpatient stay, day care, psychiatrist visits and medication) in patients who were adherent, partially adherent, and non-adherent, using a log-link function. Adherence status was included as a time-varying variable, and other baseline patient characteristics were adjusted for. UK unit costs were applied to resource use.

Results

Out of 5364 patients who were prescribed medication prior to baseline, 5.9% were non-adherent while 77.1% and 17.0% were adherent and partially adherent, respectively, at baseline. The average 6-month cost incurred by non-adherent patients was £2505 while that for adherent and partially adherent patients was £2029 and £2130 respectively. This difference was mainly due to inpatient costs. The inpatient costs incurred by non-adherent patients (£987) were almost double those for adherent patients (£475).

Conclusion

Non-adherence in schizophrenia was likely to incur more inpatient services, which may indicate poorer clinical prognosis. A study limitation is that adherence was assessed by investigators using a single-item measure.

Type
Psychotic disorders / Schizophrenia
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.